-
公开(公告)号：EP3744344A1
公开(公告)日：2020-12-02
申请号：EP20166154.3
申请日：2013-10-31
IPC分类号： A61K39/395 , C07K16/24
摘要： The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.
-
公开(公告)号：EP2914289B1
公开(公告)日：2019-05-22
申请号：EP13798260.9
申请日：2013-10-31
发明人： RAST, Markus , STEINHILBER, Wolfram , DE MUYNCK, Christian , BECKER, Gerhard , PEDERSEN, Pernille Dybendal , URBIG, Thomas , BOEHM, Thomas
IPC分类号： A61K39/395 , A61K47/18 , A61K47/26 , A61K9/19
-
3.发明公开LIQUID FORMULATION COMPRISING GM-CSF NEUTRALIZING COMPOUND 审中-公开FLUSSIGFORMULIERUNG MIT EINER GM-CSF-NEUTRALISIERENDEN VERBINDUNG
公开(公告)号：EP2914290A1
公开(公告)日：2015-09-09
申请号：EP13798590.9
申请日：2013-10-31
IPC分类号： A61K39/395 , C07K16/24
摘要： The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.
摘要翻译： 本发明涉及包含浓度为至少约20mg / ml的中和GM-CSF的化合物，张力调节剂和缓冲剂的水性制剂，其中组合物是稳定的。 考虑到长期储存，制剂的成分优选提供对中和GM-CSF的化合物的稳定性。 在优选的方面，制剂用于治疗，优选用于治疗炎性和自身免疫性疾病，优选包括过敏性和银屑病性疾病，以及关节炎和哮喘性疾病。 此外，提供了包含本发明制剂的试剂盒。
-
公开(公告)号：EP2914290B1
公开(公告)日：2020-04-01
申请号：EP13798590.9
申请日：2013-10-31
IPC分类号： A61K39/395 , C07K16/24
-
5.发明公开LYOPHILIZED FORMULATION COMPRISING GM-CSF NEUTRALIZING COMPOUND 审中-公开LYOPHILISIERTE FORMULIERUNG MIT EINER GM-CSF-NEUTRALISIERENDEN VERBINDUNG
公开(公告)号：EP2914289A1
公开(公告)日：2015-09-09
申请号：EP13798260.9
申请日：2013-10-31
发明人： RAST, Markus , STEINHILBER, Wolfram , DE MUYNCK, Christian , BECKER, Gerhard , PEDERSEN, Pernille Dybendal , URBIG, Thomas , BOEHM, Thomas
IPC分类号： A61K39/395 , A61K47/18 , A61K47/26 , A61K9/19
CPC分类号： A61K9/19 , A61K39/395 , A61K39/39591 , A61K47/183 , A61K47/22 , A61K47/26 , C07K16/243 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/94
摘要： The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilization, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.
摘要翻译： 本发明涉及包含至少20mg / ml中和GM-CSF的化合物，冻干保护剂和氨基酸和/或缓冲液的含水制剂。 考虑到冻干，储存和重建，制剂的成分优选提供对中和GM-CSF的化合物的稳定性。 在优选的方面，制剂例如 重建后用于治疗，优选用于治疗炎性和自身免疫性疾病，优选包括过敏性和银屑病性疾病，以及关节炎和哮喘性疾病。 此外，提供了包含本发明制剂的试剂盒。
-
-
-
-
搜索结果
5 条记录 (耗时 0.208 秒)
